BioLineRx Ltd. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
BLRX Nasdaq 2836 www.biolinerx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for BioLineRx Ltd.

BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026) - Sep 10th, 2026 5:00 am
BLRX: New GLIX1 Data Touts Synergies - Sep 1st, 2026 6:05 am
BioLine Rx Ltd (BLRX) (Q2 2026) Earnings Call Highlights: Advancing GLIX1 Pipeline and ... - Aug 31st, 2026 3:00 pm
BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Aug 31st, 2026 5:00 am
BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement - Aug 28th, 2026 6:00 am
BioLineRx to Report Second Quarter 2026 Results on August 31, 2026 - Aug 25th, 2026 5:00 am
BioLineRx and Hemispherian AS to Present Data Demonstrating Strong Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancers at ESMO 2026 - Jul 20th, 2026 5:00 am
BioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft Model - Jul 8th, 2026 5:00 am
BioLine Rx Ltd (BLRX) Q1 2026 Earnings Call Highlights: Revenue Growth and Strategic ... - Jun 2nd, 2026 7:01 pm
BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update - May 27th, 2026 5:00 am
BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting - May 22nd, 2026 5:00 am
BioLineRx to Report First Quarter 2026 Results on May 27, 2026 - May 20th, 2026 5:00 am
BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Patient-Derived Xenografts - May 19th, 2026 5:00 am
BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM) - Apr 28th, 2026 5:00 am
BioLine Rx Ltd (BLRX) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Financial ... - Nov 28th, 2025 6:00 pm
BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update - Nov 24th, 2025 5:00 am